Stem Cell Caution
By Richard Hayes,
Tom Paine
| 05. 24. 2006
Support for stem cell research has become a cause célèbre among Democrats. Last year New Jersey Senator Jon Corzine made it a big part of his successful campaign for Governor. This year New York Attorney General Elliott Spitzer is proposing a $1 billion stem cell bond issue as part of his own gubernatorial campaign. In Missouri Democrat Claire McCaskill is spotlighting stem cell research in her effort to unseat Republican Senator Jim Talent. And this week marks the one year anniversary of the passage of Castle-DeGette, the House bill that expands federal funding for stem cell research. Senate Democrats are rallying to push for a vote as soon as possible on the Senate version of this bill.
I'm a life-long liberal Democrat, pro-choice on abortion and a supporter of innovative medical research. I believe that stem cell research holds promise, and that the Bush administration's policies are unnecessarily restrictive. Now stem cells appear to be giving Democrats a potent vote-getting wedge issue.
Why am I worried about this?
I'm worried because in their over-the-top enthusiasm for stem cell and cloning...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...